马来西亚药用植物产品 SKF7® 对 SARS-CoV-2 的体外药效研究

2区医学 Q1 Medicine

BMC Complementary and Alternative Medicine Pub Date : 2024-09-11 DOI:10.1186/s12906-024-04628-6

Mohd Ridzuan Mohd Abd Razak, Nur Hana Md Jelas, Nor Azrina Norahmad, Norazlan Mohmad Misnan, Amirrudin Muhammad, Noorsofiana Padlan, Muhammad Nor Farhan Sa’at, Murizal Zainol, Ami Fazlin Syed Mohamed

{"title":"马来西亚药用植物产品 SKF7® 对 SARS-CoV-2 的体外药效研究","authors":"Mohd Ridzuan Mohd Abd Razak, Nur Hana Md Jelas, Nor Azrina Norahmad, Norazlan Mohmad Misnan, Amirrudin Muhammad, Noorsofiana Padlan, Muhammad Nor Farhan Sa’at, Murizal Zainol, Ami Fazlin Syed Mohamed","doi":"10.1186/s12906-024-04628-6","DOIUrl":null,"url":null,"abstract":"In early 2020, COVID-19 pandemic has mobilized researchers in finding new remedies including repurposing of medicinal plant products focusing on direct-acting antiviral and host-directed therapies. In this study, we performed an in vitro investigation on the standardized Marantodes pumilum extract (SKF7®) focusing on anti-SARS-CoV-2 and anti-inflammatory activities. Anti-SARS-CoV-2 potential of the SKF7® was evaluated in SARS-CoV-2-infected Vero E6 cells and SARS-CoV-2-infected A549 cells by cytopathic effect-based assay and RT-qPCR, respectively. Target based assays were performed on the SKF7® against the S1-ACE2 interaction and 3CL protease activities. Anti-inflammatory activity of the SKF7® was evaluated by nitric oxide inhibitory and TLR2/TLR4 receptor blocker assays. The SKF7® inhibited wild-type Wuhan (EC50 of 21.99 µg/mL) and omicron (EC50 of 16.29 µg/mL) SARS-CoV-2 infections in Vero-E6 cells. The SKF7® also inhibited the wild-type SARS-CoV-2 infection in A549 cells (EC50 value of 6.31 µg/mL). The SKF7® prominently inhibited 3CL protease activity. The SKF7® inhibited the LPS induced-TLR4 response with the EC50 of 16.19 µg/mL. In conclusion, our in vitro study highlighted anti-SARS-CoV-2 and anti-inflammatory potentials of the SKF7®. Future pre-clinical in vivo studies focusing on antiviral and immunomodulatory potentials of the SKF7® in affecting the COVID-19 pathogenesis are warranted.","PeriodicalId":9132,"journal":{"name":"BMC Complementary and Alternative Medicine","volume":"17 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"In vitro study on efficacy of SKF7®, a Malaysian medicinal plant product against SARS-CoV-2\",\"authors\":\"Mohd Ridzuan Mohd Abd Razak, Nur Hana Md Jelas, Nor Azrina Norahmad, Norazlan Mohmad Misnan, Amirrudin Muhammad, Noorsofiana Padlan, Muhammad Nor Farhan Sa’at, Murizal Zainol, Ami Fazlin Syed Mohamed\",\"doi\":\"10.1186/s12906-024-04628-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In early 2020, COVID-19 pandemic has mobilized researchers in finding new remedies including repurposing of medicinal plant products focusing on direct-acting antiviral and host-directed therapies. In this study, we performed an in vitro investigation on the standardized Marantodes pumilum extract (SKF7®) focusing on anti-SARS-CoV-2 and anti-inflammatory activities. Anti-SARS-CoV-2 potential of the SKF7® was evaluated in SARS-CoV-2-infected Vero E6 cells and SARS-CoV-2-infected A549 cells by cytopathic effect-based assay and RT-qPCR, respectively. Target based assays were performed on the SKF7® against the S1-ACE2 interaction and 3CL protease activities. Anti-inflammatory activity of the SKF7® was evaluated by nitric oxide inhibitory and TLR2/TLR4 receptor blocker assays. The SKF7® inhibited wild-type Wuhan (EC50 of 21.99 µg/mL) and omicron (EC50 of 16.29 µg/mL) SARS-CoV-2 infections in Vero-E6 cells. The SKF7® also inhibited the wild-type SARS-CoV-2 infection in A549 cells (EC50 value of 6.31 µg/mL). The SKF7® prominently inhibited 3CL protease activity. The SKF7® inhibited the LPS induced-TLR4 response with the EC50 of 16.19 µg/mL. In conclusion, our in vitro study highlighted anti-SARS-CoV-2 and anti-inflammatory potentials of the SKF7®. Future pre-clinical in vivo studies focusing on antiviral and immunomodulatory potentials of the SKF7® in affecting the COVID-19 pathogenesis are warranted.\",\"PeriodicalId\":9132,\"journal\":{\"name\":\"BMC Complementary and Alternative Medicine\",\"volume\":\"17 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-09-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMC Complementary and Alternative Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1186/s12906-024-04628-6\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Complementary and Alternative Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s12906-024-04628-6","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

2020 年初，COVID-19 大流行促使研究人员寻找新的疗法，包括重新利用药用植物产品，重点是直接作用抗病毒和宿主导向疗法。在本研究中，我们对标准化的马兰头提取物（SKF7®）进行了体外研究，重点研究其抗SARS-CoV-2和抗炎活性。在SARS-CoV-2感染的Vero E6细胞和SARS-CoV-2感染的A549细胞中，分别通过基于细胞病理效应的检测和RT-qPCR对SKF7®的抗SARS-CoV-2潜力进行了评估。对 SKF7® 的 S1-ACE2 相互作用和 3CL 蛋白酶活性进行了靶标检测。一氧化氮抑制和 TLR2/TLR4 受体阻断试验评估了 SKF7® 的抗炎活性。SKF7® 可抑制 Vero-E6 细胞中野生型武汉病毒（EC50 为 21.99 µg/mL）和欧米茄病毒（EC50 为 16.29 µg/mL）的 SARS-CoV-2 感染。SKF7® 还能抑制野生型 SARS-CoV-2 在 A549 细胞中的感染（EC50 值为 6.31 µg/mL）。SKF7® 能显著抑制 3CL 蛋白酶的活性。SKF7® 可抑制 LPS 诱导的 TLR4 反应，其 EC50 值为 16.19 µg/mL。总之，我们的体外研究强调了 SKF7® 的抗 SARS-CoV-2 和抗炎潜力。未来的临床前体内研究应侧重于 SKF7® 在影响 COVID-19 发病机制方面的抗病毒和免疫调节潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

In vitro study on efficacy of SKF7®, a Malaysian medicinal plant product against SARS-CoV-2

查看原文本刊更多论文

In vitro study on efficacy of SKF7®, a Malaysian medicinal plant product against SARS-CoV-2

In early 2020, COVID-19 pandemic has mobilized researchers in finding new remedies including repurposing of medicinal plant products focusing on direct-acting antiviral and host-directed therapies. In this study, we performed an in vitro investigation on the standardized Marantodes pumilum extract (SKF7®) focusing on anti-SARS-CoV-2 and anti-inflammatory activities. Anti-SARS-CoV-2 potential of the SKF7® was evaluated in SARS-CoV-2-infected Vero E6 cells and SARS-CoV-2-infected A549 cells by cytopathic effect-based assay and RT-qPCR, respectively. Target based assays were performed on the SKF7® against the S1-ACE2 interaction and 3CL protease activities. Anti-inflammatory activity of the SKF7® was evaluated by nitric oxide inhibitory and TLR2/TLR4 receptor blocker assays. The SKF7® inhibited wild-type Wuhan (EC50 of 21.99 µg/mL) and omicron (EC50 of 16.29 µg/mL) SARS-CoV-2 infections in Vero-E6 cells. The SKF7® also inhibited the wild-type SARS-CoV-2 infection in A549 cells (EC50 value of 6.31 µg/mL). The SKF7® prominently inhibited 3CL protease activity. The SKF7® inhibited the LPS induced-TLR4 response with the EC50 of 16.19 µg/mL. In conclusion, our in vitro study highlighted anti-SARS-CoV-2 and anti-inflammatory potentials of the SKF7®. Future pre-clinical in vivo studies focusing on antiviral and immunomodulatory potentials of the SKF7® in affecting the COVID-19 pathogenesis are warranted.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

BMC Complementary and Alternative Medicine INTEGRATIVE & COMPLEMENTARY MEDICINE-

CiteScore

7.00

自引率

0.00%

发文量

审稿时长

3 months

期刊介绍： BMC Complementary Medicine and Therapies is an open access journal publishing original peer-reviewed research articles on interventions and resources that complement or replace conventional therapies, with a specific emphasis on research that explores the biological mechanisms of action, as well as their efficacy, safety, costs, patterns of use and/or implementation.